Hims & Hers Reports Wider Loss Amid Shift to Branded Weight-Loss Drugs
Hims & Hers Health (HIMS) has reported a wider-than-expected net loss for the second quarter, primarily due to its strategic shift towards branded weight-loss drugs. For the three months ending June 30, the company recorded a net loss of 37 cents per share, significantly higher than analysts' consensus estimate of a 1-cent loss, as reported by LSEG data. Following this announcement, shares of Hims & Hers fell by 6% in after-hours trading.
The financial results reflect the increased costs associated with the company's pivot towards branded GLP-1 obesity treatments and an expanding international presence. During this quarter, Hims incurred $4.6 million in restructuring charges connected to this transition, leading to expectations that gross margins will remain below historical levels for the foreseeable future.
Despite this earnings miss, Hims & Hers has raised its full-year revenue outlook to between $3.1 billion and $3.3 billion, an increase from its previous forecast of $2.8 billion to $3 billion. This revised guidance includes contributions from Eucalyptus, an Australian digital health company that Hims agreed to acquire in February. Chief Financial Officer Yemi Okupe expressed confidence in the company's ability to establish strong cash flows in the future, stating, "Do we have the ability to set the foundation for strong cash flows in the future? Resoundingly, the answer is 'yes'."
Paul Cerro, chief investment officer at Cedar Grove Capital Management and a Hims shareholder, acknowledged the profitability challenges stemming from international markets but maintained that the long-term revenue potential remains promising. He noted, "It's not that it's a bad business. It's just not as lucrative."
Hims has been focusing on personalized treatments amidst increasing regulatory scrutiny of compounded drugs. The company is currently testing ingredients used in compounded peptide treatments and is optimistic about offering such products at scale, pending regulatory approval in the U.S. An FDA advisory panel recently supported reversing restrictions on the manufacture of six peptides, although agency staff cautioned that evidence regarding their safety and effectiveness is still limited.
Raul Shah, chief investment officer at DocShah Financial, predicts that Hims will return to its historical profit margins within five years as its international and weight-loss offerings mature.




